KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations
A plain-language account of the KRYSTAL-12 trial, written for patients and carers, explaining how adagrasib compared with docetaxel chemotherapy in previously treated KRAS G12C lung cancer.
Overview
Plain language summary of the phase 3 KRYSTAL-12 trial, which randomised previously treated patients with KRAS G12C-mutated non-small-cell lung cancer to the KRAS G12C inhibitor adagrasib or docetaxel. Written by the trial investigators for a non-specialist reader, it restates the design, the progression-free survival result and the side-effect profile of the primary publication.
Europe PMC indexes no abstract for this article, so OnCo carries no figures from it; the trial's own record holds the primary result from the pivotal publication.
- Restates the KRYSTAL-12 result in plain language for patients: adagrasib compared with docetaxel after prior treatment for KRAS G12C lung cancer.
Useful for a patient offered adagrasib after chemotherapy or immunotherapy who wants the trial explained without jargon. It adds no new data; the primary KRYSTAL-12 publication and the trial page remain the reference for the numbers.
- A plain language summary of a published trial, not a new analysis; it reports no results beyond the primary publication.
- No abstract is indexed on Europe PMC, so no figures have been transcribed here.
Similar pages
not linked directly; found by shared links- TrialPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Bristol Myers Squibb, Non-small-cell lung cancer.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Bristol Myers Squibb, Non-small-cell lung cancer.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Bristol Myers Squibb, Non-small-cell lung cancer.
- TrialKrascendo 1
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS, Non-small-cell lung cancer.
- PersonFerdinandos Skoulidis
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS, Non-small-cell lung cancer.
- PersonKevan M. Shokat
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS, Non-small-cell lung cancer.
- PersonPasi A. Jänne
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS, Non-small-cell lung cancer.
- TreatmentResolution ctDx FIRST
Shares Adagrasib, KRAS, Non-small-cell lung cancer.